KR101808895B1 - 세포독성 디펩티드의 동결건조 제제 - Google Patents

세포독성 디펩티드의 동결건조 제제 Download PDF

Info

Publication number
KR101808895B1
KR101808895B1 KR1020137031096A KR20137031096A KR101808895B1 KR 101808895 B1 KR101808895 B1 KR 101808895B1 KR 1020137031096 A KR1020137031096 A KR 1020137031096A KR 20137031096 A KR20137031096 A KR 20137031096A KR 101808895 B1 KR101808895 B1 KR 101808895B1
Authority
KR
South Korea
Prior art keywords
melphalan
delete delete
solution
freeze
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137031096A
Other languages
English (en)
Korean (ko)
Other versions
KR20140041497A (ko
Inventor
잭 스피라
프레드릭 레만
Original Assignee
온코펩타이드즈 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코펩타이드즈 아베 filed Critical 온코펩타이드즈 아베
Publication of KR20140041497A publication Critical patent/KR20140041497A/ko
Application granted granted Critical
Publication of KR101808895B1 publication Critical patent/KR101808895B1/ko
Assigned to 온코펩타이드즈 이노베이션 아베 reassignment 온코펩타이드즈 이노베이션 아베 권리의 전부이전등록 Assignors: 온코펩타이드즈 아베
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A61K38/105—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020137031096A 2011-04-28 2012-04-25 세포독성 디펩티드의 동결건조 제제 Active KR101808895B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1150371-1 2011-04-28
SE1150371 2011-04-28
US201161535126P 2011-09-15 2011-09-15
US61/535,126 2011-09-15
PCT/EP2012/057577 WO2012146625A1 (en) 2011-04-28 2012-04-25 Lyophilized preparation of cytotoxic dipeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177035122A Division KR102122416B1 (ko) 2011-04-28 2012-04-25 세포독성 디펩티드의 동결건조 제제

Publications (2)

Publication Number Publication Date
KR20140041497A KR20140041497A (ko) 2014-04-04
KR101808895B1 true KR101808895B1 (ko) 2017-12-13

Family

ID=47071620

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137031096A Active KR101808895B1 (ko) 2011-04-28 2012-04-25 세포독성 디펩티드의 동결건조 제제
KR1020177035122A Active KR102122416B1 (ko) 2011-04-28 2012-04-25 세포독성 디펩티드의 동결건조 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177035122A Active KR102122416B1 (ko) 2011-04-28 2012-04-25 세포독성 디펩티드의 동결건조 제제

Country Status (29)

Country Link
US (8) US20140128462A1 (cg-RX-API-DMAC7.html)
EP (4) EP3656393B1 (cg-RX-API-DMAC7.html)
JP (1) JP6042412B2 (cg-RX-API-DMAC7.html)
KR (2) KR101808895B1 (cg-RX-API-DMAC7.html)
CN (2) CN103547279A (cg-RX-API-DMAC7.html)
AU (1) AU2012247545B2 (cg-RX-API-DMAC7.html)
BR (2) BR112013027584B1 (cg-RX-API-DMAC7.html)
CA (2) CA3024230C (cg-RX-API-DMAC7.html)
CY (2) CY1119453T1 (cg-RX-API-DMAC7.html)
DK (3) DK2701720T3 (cg-RX-API-DMAC7.html)
ES (2) ES2642676T3 (cg-RX-API-DMAC7.html)
FI (1) FIC20230004I1 (cg-RX-API-DMAC7.html)
FR (1) FR23C1000I2 (cg-RX-API-DMAC7.html)
HR (2) HRP20221355T1 (cg-RX-API-DMAC7.html)
HU (3) HUE060783T2 (cg-RX-API-DMAC7.html)
IL (3) IL228889A0 (cg-RX-API-DMAC7.html)
LT (3) LT3656393T (cg-RX-API-DMAC7.html)
LU (1) LUC00291I2 (cg-RX-API-DMAC7.html)
MX (1) MX345102B (cg-RX-API-DMAC7.html)
NL (1) NL301206I2 (cg-RX-API-DMAC7.html)
NO (1) NO2023004I1 (cg-RX-API-DMAC7.html)
PL (3) PL2701720T3 (cg-RX-API-DMAC7.html)
PT (2) PT2701720T (cg-RX-API-DMAC7.html)
RS (3) RS60719B1 (cg-RX-API-DMAC7.html)
RU (1) RU2597154C2 (cg-RX-API-DMAC7.html)
SI (2) SI3228319T1 (cg-RX-API-DMAC7.html)
SM (3) SMT202200450T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012146625A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201308765B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3228319T1 (sl) 2011-04-28 2020-10-30 Oncopeptides Ab Liofiliziran pripravek citotoksičnih dipeptidov
JP5827178B2 (ja) * 2012-06-05 2015-12-02 北越紀州製紙株式会社 セルロース多孔質体及びその製造方法
JP6284945B2 (ja) * 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤
KR102226082B1 (ko) * 2012-10-26 2021-03-10 온코펩타이드즈 아베 멜팔란 플루펜아미드의 동결건조 제제
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
US10369077B2 (en) * 2017-05-31 2019-08-06 Adienne Pharma & Biotech Sa Multi chamber flexible bag and methods of using the same
US10507165B2 (en) 2017-05-31 2019-12-17 Adienne Pharma & Biotech Sa Multi chamber flexible bag and methods of using same
WO2020079165A1 (en) * 2018-10-18 2020-04-23 Oncopeptides Ab Compounds containing deuterium
WO2020201542A1 (en) 2019-04-03 2020-10-08 Oncopeptides Ab Treatment of al amyloidosis with melflufen
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
US11503829B2 (en) * 2020-05-08 2022-11-22 Gjb Applied Technologies, Inc. Pesticidal compositions and related methods
KR20230131815A (ko) * 2020-08-19 2023-09-14 셀액트 파마 게엠베하 에토포시드 토니리베이트 제제
US12077809B2 (en) 2021-04-27 2024-09-03 Enplas Corporation Freeze-dried structure and producing method thereof
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
US20240307480A1 (en) 2021-07-08 2024-09-19 Oncopeptides Ab Melflufen for use in the treatment of multiple myeloma
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
KR102757193B1 (ko) * 2021-10-19 2025-01-21 단국대학교 천안캠퍼스 산학협력단 피리미딘-2,4-다이온 유도체를 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations
CN116617376A (zh) * 2022-09-28 2023-08-22 杭州芯递力生物科技有限公司 一种抗原肽组合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034099A1 (en) 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition
US20040097421A1 (en) 2000-06-13 2004-05-20 Rolf Lewensohn Melphalan derivatives and their use as cancer chemotherapeutic drugs

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1997651A (en) * 1933-11-08 1935-04-16 Watford Engineering Works Ltd Washing device comprising shower pipes
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
GB8727157D0 (en) * 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
JP3176716B2 (ja) 1991-06-21 2001-06-18 武田薬品工業株式会社 溶解性が向上した難水溶性薬物組成物
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
JP2005508220A (ja) 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
CN100346784C (zh) * 2002-02-22 2007-11-07 先灵公司 抗肿瘤剂,特别是替莫唑胺的药物制剂,其制备方法和用途
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
JP4603816B2 (ja) * 2003-05-16 2010-12-22 オプティスキャン ピーティーワイ リミテッド 光コネクタ
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
EP1796647B1 (en) 2004-08-12 2010-08-11 Schering Corporation Stable pegylated interferon formulation
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US7754720B2 (en) 2006-07-07 2010-07-13 Gilead Sciences, Inc. Pyridazine compound and use thereof
PT2101731T (pt) 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
CN101584669B (zh) * 2009-06-19 2010-12-29 江苏奥赛康药业有限公司 美法仑冻干粉针剂
WO2011078782A1 (en) * 2009-12-22 2011-06-30 Oncopeptides Ab A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer
AR077384A1 (es) 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
HRP20201241T1 (hr) * 2011-04-15 2020-11-27 Janssen Pharmaceutica N.V. Nanosuspenzije lijeka osušene zamrzavanjem
SI3228319T1 (sl) 2011-04-28 2020-10-30 Oncopeptides Ab Liofiliziran pripravek citotoksičnih dipeptidov
JP6284945B2 (ja) 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097421A1 (en) 2000-06-13 2004-05-20 Rolf Lewensohn Melphalan derivatives and their use as cancer chemotherapeutic drugs
US20040034099A1 (en) 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Excipients and Food Chem. 1(1), 2010, 41-54

Also Published As

Publication number Publication date
RS63747B1 (sr) 2022-12-30
PT2701720T (pt) 2017-10-20
CA2833500A1 (en) 2012-11-01
US20200345848A1 (en) 2020-11-05
DK3228319T3 (da) 2020-09-07
NL301206I1 (en) 2022-12-14
PL3656393T3 (pl) 2023-01-16
IL228889A0 (en) 2013-12-31
WO2012146625A1 (en) 2012-11-01
BR122019017088B1 (pt) 2021-11-16
US11344622B2 (en) 2022-05-31
IL265457B (en) 2021-02-28
RU2013152751A (ru) 2015-06-10
BR112013027584B1 (pt) 2020-11-03
CY1119453T1 (el) 2018-03-07
US20220323585A1 (en) 2022-10-13
EP4122482A1 (en) 2023-01-25
IL265457A (en) 2019-05-30
LTC2701720I2 (cg-RX-API-DMAC7.html) 2024-09-25
LT2701720T (lt) 2017-11-10
IL272429A (en) 2020-03-31
RS60719B1 (sr) 2020-09-30
SMT202200450T1 (it) 2023-01-13
CA3024230C (en) 2022-10-18
FR23C1000I2 (fr) 2024-03-15
MX345102B (es) 2017-01-16
LT3656393T (lt) 2022-12-12
CA2833500C (en) 2019-01-08
EP3228319A1 (en) 2017-10-11
ZA201308765B (en) 2016-02-24
PL2701720T3 (pl) 2017-12-29
US20200009252A1 (en) 2020-01-09
HUS2300005I1 (hu) 2023-02-28
RU2597154C2 (ru) 2016-09-10
RS56462B1 (sr) 2018-01-31
EP3656393B1 (en) 2022-08-24
SI3228319T1 (sl) 2020-10-30
SMT202000447T1 (it) 2020-09-10
NZ617197A (en) 2015-06-26
JP2014512402A (ja) 2014-05-22
KR20140041497A (ko) 2014-04-04
AU2012247545A1 (en) 2013-10-31
HRP20221355T1 (hr) 2022-12-23
IL272429B (en) 2022-05-01
US20170049894A1 (en) 2017-02-23
US20140128462A1 (en) 2014-05-08
CY1123242T1 (el) 2021-10-29
NO2023004I1 (no) 2023-01-16
US10322182B2 (en) 2019-06-18
JP6042412B2 (ja) 2016-12-14
US20190240332A1 (en) 2019-08-08
CN103547279A (zh) 2014-01-29
ES2642676T3 (es) 2017-11-17
DK2701720T3 (en) 2017-10-09
DK3656393T3 (da) 2022-11-14
ES2930140T3 (es) 2022-12-07
US11896668B2 (en) 2024-02-13
US20240358838A1 (en) 2024-10-31
EP3656393A1 (en) 2020-05-27
NL301206I2 (nl) 2023-01-24
BR112013027584A2 (pt) 2016-09-06
MX2013012545A (es) 2014-04-16
SMT201700459T1 (it) 2017-11-15
US20200121794A1 (en) 2020-04-23
US10543274B2 (en) 2020-01-28
KR20170140409A (ko) 2017-12-20
HUE037863T2 (hu) 2018-09-28
LUC00291I2 (cg-RX-API-DMAC7.html) 2025-05-12
HRP20171523T1 (hr) 2017-11-17
AU2012247545B2 (en) 2016-08-11
CN108096563A (zh) 2018-06-01
EP3228319B1 (en) 2020-06-03
KR102122416B1 (ko) 2020-06-12
SI2701720T1 (sl) 2017-11-30
CA3024230A1 (en) 2012-11-01
PL3228319T3 (pl) 2021-02-08
EP2701720A1 (en) 2014-03-05
EP2701720B1 (en) 2017-07-12
FIC20230004I1 (fi) 2023-01-19
US10869928B2 (en) 2020-12-22
PT3656393T (pt) 2022-11-03
FR23C1000I1 (fr) 2023-03-10
HUE060783T2 (hu) 2023-04-28

Similar Documents

Publication Publication Date Title
US11896668B2 (en) Lyophilized preparation of cytotoxic dipeptides
HK1250492A1 (zh) 细胞毒性二肽的冻干制剂
HK40081253A (en) Lyophilized preparation of cytotoxic dipeptides
HK40018864A (en) Lyophilized preparation of cytotoxic dipeptides
HK40018864B (en) Lyophilized preparation of cytotoxic dipeptides
HK1245124A1 (en) Lyophilized preparation of cytotoxic dipeptides
HK1245124B (en) Lyophilized preparation of cytotoxic dipeptides

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170208

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20170208

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170612

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170915

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20171205

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20171207

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20171207

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20201117

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20201117

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20211118

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20211118

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20221027

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20221027

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20241029

Start annual number: 8

End annual number: 8